Loading...

Alterity Therapeutics

ASX:ATH
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ATH
ASX
A$33M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The last earnings update was 82 days ago. More info.


Add to Portfolio Compare Print
  • Alterity Therapeutics has significant price volatility in the past 3 months.
ATH Share Price and Events
7 Day Returns
-2.6%
ASX:ATH
3.3%
AU Biotechs
2.9%
AU Market
1 Year Returns
-11.6%
ASX:ATH
11.9%
AU Biotechs
4.3%
AU Market
ATH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alterity Therapeutics (ATH) -2.6% -13.6% -5% -11.6% -54.2% -77%
AU Biotechs 3.3% 8.6% 12.9% 11.9% 80.3% 167.3%
AU Market 2.9% 3.2% 5.5% 4.3% 21% 9.7%
1 Year Return vs Industry and Market
  • ATH underperformed the Biotechs industry which returned 11.9% over the past year.
  • ATH underperformed the Market in Australia which returned 4.3% over the past year.
Price Volatility
ATH
Industry
5yr Volatility vs Market

ATH Value

 Is Alterity Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alterity Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is A$0.038.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alterity Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alterity Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ATH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.02
ASX:ATH Share Price ** ASX (2019-05-21) in AUD A$0.04
Global Biotechs Industry PE Ratio Median Figure of 76 Publicly-Listed Biotechs Companies 20.55x
Australia Market PE Ratio Median Figure of 542 Publicly-Listed Companies 16.09x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alterity Therapeutics.

ASX:ATH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ATH Share Price ÷ EPS (both in AUD)

= 0.04 ÷ -0.02

-2.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alterity Therapeutics is loss making, we can't compare its value to the Global Biotechs industry average.
  • Alterity Therapeutics is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Alterity Therapeutics's expected growth come at a high price?
Raw Data
ASX:ATH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 57 Publicly-Listed Biotechs Companies 1.22x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alterity Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alterity Therapeutics's assets?
Raw Data
ASX:ATH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.02
ASX:ATH Share Price * ASX (2019-05-21) in AUD A$0.04
Australia Biotechs Industry PB Ratio Median Figure of 43 Publicly-Listed Biotechs Companies 2.93x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.65x
ASX:ATH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ATH Share Price ÷ Book Value per Share (both in AUD)

= 0.04 ÷ 0.02

1.87x

* Primary Listing of Alterity Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alterity Therapeutics is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Alterity Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alterity Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ATH Future Performance

 How is Alterity Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alterity Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alterity Therapeutics expected to grow at an attractive rate?
  • Unable to compare Alterity Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Alterity Therapeutics's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Alterity Therapeutics's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:ATH Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 10.5%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 8.8%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ATH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ATH Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ASX:ATH Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -12 -10
2018-09-30 4 -9 -9
2018-06-30 3 -6 -8
2018-03-31 3 -6 -8
2017-12-31 3 -6 -8
2017-09-30 3 -6 -8
2017-06-30 3 -6 -8
2017-03-31 4 -3 -8
2016-12-31 4 -1 -9
2016-09-30 4 -4 -8
2016-06-30 5 -7 -8
2016-03-31 5 -9 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Alterity Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Alterity Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ATH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Alterity Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ATH Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ASX:ATH Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.02
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.02
2016-06-30 -0.01
2016-03-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alterity Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Alterity Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Alterity Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Alterity Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Alterity Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alterity Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ATH Past Performance

  How has Alterity Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alterity Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alterity Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Alterity Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alterity Therapeutics's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alterity Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alterity Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ATH Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.34 -9.99 4.39 10.30
2018-09-30 3.83 -9.13 4.37 8.50
2018-06-30 3.33 -8.27 4.34 6.70
2018-03-31 3.03 -7.89 4.13 5.43
2017-12-31 2.73 -7.51 3.92 4.15
2017-09-30 2.94 -7.52 3.94 4.93
2017-06-30 3.16 -7.54 3.97 5.70
2017-03-31 3.55 -8.03 3.82 7.10
2016-12-31 3.94 -8.53 3.68 8.50
2016-09-30 4.42 -8.13 3.65 9.04
2016-06-30 4.90 -7.73 3.61 9.59
2016-03-31 5.41 -7.61 4.28 10.62
2015-12-31 5.93 -7.49 4.95 11.66
2015-09-30 6.21 -6.69 4.73 11.98
2015-06-30 6.49 -5.89 4.51 12.30
2015-03-31 8.24 -6.27 5.51 12.82
2014-12-31 9.98 -6.65 3.35 13.34
2014-09-30 9.10 -9.99 3.35 14.13
2014-06-30 8.21 -13.33 4.93 14.91
2014-03-31 6.10 -12.36 3.03 13.13
2013-12-31 3.98 -11.38 2.72 11.34
2013-09-30 4.31 -9.59 2.82 9.77
2013-06-30 4.64 -7.79 2.91 8.20
2013-03-31 4.30 -6.99 2.92 7.03
2012-12-31 3.97 -6.20 2.97 5.81
2012-09-30 3.25 -5.72 2.68 5.02
2012-06-30 2.53 -5.24 2.37 4.25

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alterity Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alterity Therapeutics has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alterity Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alterity Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alterity Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ATH Health

 How is Alterity Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alterity Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alterity Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alterity Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alterity Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Alterity Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alterity Therapeutics Company Filings, last reported 4 months ago.

ASX:ATH Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 10.92 0.00 8.38
2018-09-30 10.92 0.00 8.38
2018-06-30 16.08 0.00 15.24
2018-03-31 16.08 0.00 15.24
2017-12-31 20.12 0.00 20.07
2017-09-30 20.12 0.00 20.07
2017-06-30 23.69 0.00 21.88
2017-03-31 23.69 0.00 21.88
2016-12-31 27.56 0.00 28.34
2016-09-30 27.56 0.00 28.34
2016-06-30 31.37 0.00 28.59
2016-03-31 31.37 0.00 28.59
2015-12-31 36.24 0.00 29.06
2015-09-30 36.24 0.00 29.06
2015-06-30 39.11 0.00 34.91
2015-03-31 39.11 0.00 34.91
2014-12-31 36.51 0.00 29.05
2014-09-30 36.51 0.00 29.05
2014-06-30 37.69 0.00 34.17
2014-03-31 37.69 0.00 34.17
2013-12-31 19.79 0.84 19.30
2013-09-30 19.79 0.84 19.30
2013-06-30 13.97 0.80 13.35
2013-03-31 13.97 0.80 13.35
2012-12-31 9.47 0.75 8.84
2012-09-30 9.47 0.75 8.84
2012-06-30 5.62 0.30 5.64
  • Alterity Therapeutics has no debt.
  • Alterity Therapeutics has no debt compared to 5 years ago when it was 4.2%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alterity Therapeutics has less than a year of cash runway based on current free cash flow.
  • Alterity Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.7% each year.
X
Financial health checks
We assess Alterity Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alterity Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ATH Dividends

 What is Alterity Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alterity Therapeutics dividends.
If you bought A$2,000 of Alterity Therapeutics shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alterity Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alterity Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ATH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.7%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:ATH Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alterity Therapeutics has not reported any payouts.
  • Unable to verify if Alterity Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alterity Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alterity Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Alterity Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alterity Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alterity Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ATH Management

 What is the CEO of Alterity Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Geoffrey Kempler
COMPENSATION A$644,152
AGE 63
TENURE AS CEO 13.9 years
CEO Bio

Mr. Geoffrey Paul Kempler, B.Sc, Grad.Dip.App.Soc.Psych, co-founded Prana Biotechnology Ltd. and has been its Chief Executive Officer since June 15, 2005. Mr. Kempler serves as the Managing Director of Prana Biotechnology Ltd. He has been the Executive Chairman of Prana Biotechnology Ltd. since November 1997 and has been its Director since November 11, 1997. He served as the Chief Executive Officer at Prana Biotechnology Ltd. from November 1997 to August 2004. Mr. Kempler has been primarily responsible for the successful negotiation of its existing contractual relationships with Massachusetts General Hospital, the University of Melbourne and the Biomolecular Research Institute. Mr. Kempler has extensive experience in investment and business development, has managed Prana Biotechnology Ltd.'s operations to date and has been responsible for the implementation of its strategic plan and the commercialization of technology. He has been Non-Executive Chairman of Opthea Limited since November 30, 2015. Mr. Kempler is a qualified Psychologist and the Managing Director and major shareholder of Aroma Science Pty Ltd., which holds the Australian distribution and marketing rights to the Aveda range of cosmetic products. Mr. Kempler holds a B.Sc Degree in science from Monash University and Grad. Dip. App. Soc. Psych. degree from Swinburne University.

CEO Compensation
  • Geoffrey's compensation has increased whilst company is loss making.
  • Geoffrey's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Alterity Therapeutics management team in years:

7.3
Average Tenure
58
Average Age
  • The average tenure for the Alterity Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Geoffrey Kempler

TITLE
Co-Founder
COMPENSATION
A$644K
AGE
63
TENURE
13.9 yrs

Kathryn Andrews

TITLE
Chief Financial Officer
COMPENSATION
A$231K
AGE
51
TENURE
4.5 yrs

David Stamler

TITLE
Chief Medical Officer
COMPENSATION
A$630K
AGE
57
TENURE
1.9 yrs

Rudy Tanzi

TITLE
Chief Scientific Advisor and Member of Research & Development Advisory Board
TENURE
7.3 yrs

Steve Targum

TITLE
Chief Medical Advisor
TENURE
12.2 yrs

Robert Cherny

TITLE
Head of Research
TENURE
12.1 yrs

Phillip Hains

TITLE
Company Secretary
COMPENSATION
A$100K
AGE
59
TENURE
4.5 yrs
Board of Directors Tenure

Average tenure and age of the Alterity Therapeutics board of directors in years:

12.2
Average Tenure
62.5
Average Age
  • The average tenure for the Alterity Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Geoffrey Kempler

TITLE
Co-Founder
COMPENSATION
A$644K
AGE
63
TENURE
21.5 yrs

David Stamler

TITLE
Chief Medical Officer
COMPENSATION
A$630K
AGE
57
TENURE
1.9 yrs

Rudy Tanzi

TITLE
Chief Scientific Advisor and Member of Research & Development Advisory Board
TENURE
12.2 yrs

Brian Meltzer

TITLE
Non-Executive Independent Director
COMPENSATION
A$141K
AGE
64
TENURE
19.4 yrs

Lawrence Gozlan

TITLE
Non-Executive Independent Director
COMPENSATION
A$119K
AGE
39
TENURE
7.8 yrs

Colin Masters

TITLE
Member of Research & Development Advisory Board
COMPENSATION
A$241K
AGE
71
TENURE
12.2 yrs

Peter Marks

TITLE
Non-Executive Independent Director
COMPENSATION
A$119K
AGE
62
TENURE
13.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Alterity Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alterity Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ATH News

Simply Wall St News

ATH Company Info

Description

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson’s disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer’s disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer’s disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

Details
Name: Alterity Therapeutics Limited
ATH
Exchange: ASX
Founded: 1997
A$32,711,822
860,837,432
Website: http://pranabio.com
Address: Alterity Therapeutics Limited
460 Bourke Street,
Level 3,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ATH Ordinary Shares Australian Securities Exchange AU AUD 28. Mar 2000
OTCPK PRNA.F Ordinary Shares Pink Sheets LLC US USD 28. Mar 2000
DB PBN Ordinary Shares Deutsche Boerse AG DE EUR 28. Mar 2000
NasdaqCM ATHE SPONSORED ADR Nasdaq Capital Market US USD 05. Sep 2002
DB PBNN SPONSORED ADR Deutsche Boerse AG DE EUR 05. Sep 2002
Number of employees
Current staff
Staff numbers
14
Alterity Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/21 10:31
End of day share price update: 2019/05/21 00:00
Last estimates confirmation: 2018/08/31
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.